AIA Group Ltd Boosts Holdings in Abbott Laboratories $ABT

AIA Group Ltd grew its position in shares of Abbott Laboratories (NYSE:ABT) by 49.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 442,653 shares of the healthcare product maker’s stock after purchasing an additional 147,225 shares during the period. Abbott Laboratories makes up 0.7% of AIA Group Ltd’s portfolio, making the stock its 21st biggest holding. AIA Group Ltd’s holdings in Abbott Laboratories were worth $45,447,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the last quarter. State Street Corp lifted its position in Abbott Laboratories by 2.1% during the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after purchasing an additional 1,627,791 shares during the last quarter. Capital International Investors grew its stake in Abbott Laboratories by 2.6% in the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after buying an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP increased its holdings in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors increased its holdings in shares of Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after buying an additional 400,400 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $100.71 on Friday. The company has a market capitalization of $175.41 billion, a P/E ratio of 32.59, a PEG ratio of 1.73 and a beta of 0.61. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock has a 50 day moving average price of $89.89 and a two-hundred day moving average price of $102.17.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter last year, the business earned $1.26 earnings per share. The business’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 70.59%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Analyst Ratings Changes

A number of research firms recently commented on ABT. BTIG Research increased their target price on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday. Mizuho decreased their price objective on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Argus cut their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Jefferies Financial Group decreased their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Robert W. Baird started coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.61.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.